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Abstract—This paper compares three different biocompatible 
packaging covers suitable to support full implantation of multi-
panel sensors for remote monitoring of metabolism. The three 
covers have been designed, realized and implanted in mice for 30 
days. ATP and neutrophil concentrations have been measured at 
the implant site after the device was explanted, to assess the level 
of biocompatibility of the device. 
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I.  INTRODUCTION 
Highly integrated and complex systems are more and more 
required in advanced health care as well as in translational 
medicine. In particular, the continuous and simultaneous 
monitoring of several molecular metabolites can be realized 
with fully implantable multi-panel devices that integrate 
several heterogeneous systems to address different device 
functions [1]. However, several aspects need attention in this 
new area of systems integrations: coupling nano and 
biomaterials with CMOS electronics [2], security and privacy 
constrains [3], new designs in power  [4] and data transmission 
[5], and biocompatibility issues [6]. 
To reduce the effects of the foreign body reaction, an 
external biocompatible packaging is needed to ensure a correct 
integration with the surrounding tissue once the device is 
implanted. Polyurethane, among many other polymers, has 
been extensively used as an outer membrane to act as a 
biocompatible interface with the surrounding host tissue. 
In this paper, we show the realization of a packaging for an 
implantable device that consists of the integration of the 
sensing platform, the integrated circuits (ICs) and the 
powering antenna, for the continuous monitoring of drugs and 
metabolites in small animals. Potential sources of inflammation 
are attributed to the shapes and size of the device, and to the 
material used. Multi-walled carbon nanotubes (MWCNTs), 
used to enhance the sensing signal, are entrapped in a chitosan 
matrix to prevent toxicity due to their nano-particle nature. 
Parylene C was employed to prevent the leaking of potential 
hazardous substances and the corrosion of the electronics from 
the biological fluids. Two different membranes were used to 
cover the sensing part of the device and here we present and 
discuss three different solutions (Fig. 1) for the packaging. 
II. MATERIALS AND METHODS 
A. Integrated device fabrication and assembly 
The microfabrication of the sensing platforms was realized 
at the EPFL Centre of Micro-nano Technology (CMI). Silicon 
wafers with 500 nm of native oxide were chosen as substrate. 
Chip metallization was realized by evaporation of 10 nm of Ti, 
followed by 100 nm of Pt. Metal passivation was made via 
atomic layer deposition of Al2O3, followed by dry etching with 
Argon Ion Milling. Details on the microfabrication can be 
found in [7]. 
Figure 1A shows the photograph of the first implantable 
device. The passive sensing platform measures 2.2x15mm, 
and host five independent Pt working electrodes (WE) with 
common reference (RE) and counter (CE) electrodes [8]. 
Figure 1B and 1C show the photographs of the second and 
third version of the implantable device, respectively. The 
platforms measure 12x11 mm, in order to fit the size of the 
coil (12x12 mm) and the wire bonding. The platform hosts an 
array of four independent cells in the three-electrode 
configuration, WE, CE and RE, all made in Pt [9]. 
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Fig. 1. Photograph of the three versions of the implantable device. 
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B. Packagings 
For the realization of the first packaging for the electrode 
functionalization with MWCNTs, 0.1µl of a chitosan-
MWCNT suspension was then manually drop cast on the 
electrodes and dried in air. The surface of the biosensors was 
protected with a polycarbonate membrane (Cyclopore track 
etched membrane, cut off 100 nm, Whatman) and sealed with 
a fast curing medical grade silicone (Med2-4220, Nusil). The 
sensing platform and the electronic components were glued 
together using the USP class VI biocompatible glue (Loctite 
3211 USP class VI biocompatible glue, purchased from 
Loctite). Component interconnection was realized with 
aluminum wire bonding and protected with a glob top. To 
further improve parylene C adhesion and moisture penetration, 
the assembled platform was treated with silane A-174 (from 
Merck) and coated with 16µm of parylene C (from Specialty 
Coating Systems), deposited by chemical vapor deposition 
using a Comelec C-30-S Parylene deposition system. The 
outer silicon shell was realized by placing the implant into a 
Plexiglas mold (realized by micromachining) and by injecting 
the biocompatible medical-grade silicone (Med-6033 from 
Nusil). To increase the host comfort, the outer shell was made 
1mm thick and with rounded corners.  
In the second and third version of the packaging, the epoxy 
adhesive (EP42HT-2Med) system was used to assembly the 
electronic components and the sensing platform in the 
integrated device. The sensing platform was placed on the top 
of the PCB containing the ICs and the microprocessor. The 
interconnections between the pads of the sensing platform and 
the electronic components were realized with aluminum wire 
bonding and were protected with a glob top protection of 0.3 
mm. In the second version of the implantable device, all the 
edges of the device were rounded with a milling machine. Two 
subsequent 5 µm layers of Parylene C were deposited by 
chemical vapor deposition using a Comelec C-30-S Parylene 
Deposition System. Parylene C was used to cover the whole 
device but not the electrode array that needs to be in contact 
with fluids. The electrodes were functionalized with MWCNTs 
(0.1µl of a chitosan/MWCNT suspension was then manually 
drop cast on the electrodes and dried in air). Finally the device 
was covered with three layers of a biocompatible membrane 
made by epoxy-enhanced polyurethane. For the biocompatible 
outer packaging, a homogeneous solution was obtained by 
mixing 125 mg of an epoxy adhesive (EP42HT-2Med system), 
purchased by Master Bond (Hackensack, USA) as a certified 
biocompatible two-components adhesive, 112.5 mg of 
polyurethane (Sigma Aldrich), 12.5 mg of the surfactant agent 
polyethylene glycol ether (Brij®30, Sigma Aldrich), for 10 ml 
of tetrahydrofuran (THF, Sigma Aldrich) used as solvent. 
Subsequent depositions of the membrane by dip coating were 
applied at 1 h intervals and then the sensors were stored 
overnight at room temperature. A fast curing at high 
temperature (2 h at 80°C) is needed to ensure the 
biocompatibility of the resin. After this process the sensors 
were again kept overnight at room temperature, and then stored 
in PBS one day for membrane swelling 
In the third version of the implantable device, for the 
electrode functionalization with MWCNTs, 0.1µl of a 
chitosan/MWCNT suspension was then manually drop cast on 
the electrodes and dried in air. The edges of the device were 
not rounded with a milling machine, and two different 
biocompatible silicone elastomers were used to cover and 
round the edges and the bottom of the device: a first layer was 
realized with the Kwik-cast sealant (from World Precision 
Instruments), and the second more external layer with a 
certified biocompatible elastomer silicone (Nusil MED2 4220). 
The sensing part was only covered with the epoxy-enhanced 
polyurethane membrane. The overall weight and volume of the 
implantable device are 0.61 g and 0.4 cm3, respectively. 
Fig. 2 reports the scheme with the cross-sections of the 
three different implantable devices with the respective 
packaging. 
C. In-vivo biocompatibility tests, first packaging 
C57Bl/6 male mice (2 months old) were used for the 
experiments. The animals were bred and treated in accordance 
with the Swiss Federal Veterinary Office guidelines and were 
   
Fig. 2. Schematics of the three implantable devices: the first (A), the second (B), and the third (C). 
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kept in specific pathogen-free animal facility. Experiments 
were approved by ”Dipartimento della Sanità e Socialità” with 
authorization numbers TI-19/2010. Microchips were cleaned, 
disinfected with ethanol 70% and placed in sterile PBS 
(GIBCO). An Air Pouch (AP) was created by subcutaneous 
injection of sterile air in the back of the mice at day 1 (5 mL) 
and day 3 (3 mL); this procedure creates a cavity of 1.5 cm 
diameter and 0.5 cm height. At day 6, mice were anesthetized 
with isoflurane 4%, shaved and locally sterilized with 
Betadine Solution; the sterile microchips were implanted and 
the cavity sutured with Vicryl 6.0 (Provet AG). As a control of 
local inflammation, bacterial lipopolysaccharide (LPS, 50 
g/mouse, LabForce AG) was injected daily into the cavity for 
the last 2 weeks of the 30 days of the experiment. As negative 
control APs were generated in the absence of any surgical 
procedure. After 30 days, the microchips were removed, the 
cavity was rinsed with 0.5mL of PBS (Gibco) and the liquid 
collected and centrifuged at 7000 rpm for 10’ at 4 °C.  
D. In-vivo biocompatibility tests, second packaging 
For biocompatibility tests, the animals were bred and 
treated in accordance with the Swiss Federal Veterinary Office 
guidelines and were kept in specific pathogen-free animal 
facility. Experiments were approved by ‘’Dipartimento della 
Sanitá e Socialitá’’ with authorization number TI-19/2010. 
Microchips were cleaned and disinfected with ethanol 70% 
and placed in sterile PBS (Gibco). An AP was created by 
subcutaneous injection of sterile air in the back of male 
C57BL/6 mice at day 1 (5 mL) and day 3 (3 mL): this 
procedure creates a cavity of 1.5 cm diameter and 0.5 cm 
height. At day 6, mice were anesthetized with isoflurane 4%, 
shaved and locally sterilized with Betadine solution; the sterile 
microchips were implanted and the cavity sutured with Vicryl 
6.0 (Provet AG). As a control of local inflammation, LPS (50 
µg/mouse, LabForce AG) was injected daily into the cavity for 
the last 2 weeks of the 30 days of the experiment. As negative 
control APs were generated in the absence of any surgical 
procedure. As further control commercial chips (DATA 
MARS) were injected through sterile needle. After 30 days, 
the microchips were removed, the cavity was rinsed with 0.5 
mL of PBS (Gibco) and the liquid collected and centrifuged at 
7000 rpm for 10 min at 4 °C.  
E. In-vivo biocompatibility tests, third packaging 
C57Bl/6 male mice (2 months old) were used for the 
experiments. The animals were bred and treated in accordance 
with the Swiss Federal Veterinary Office guidelines and were 
kept in specific pathogen-free animal facility. Experiments 
were approved by ”Dipartimento della Sanità e Socialità” with 
authorization number TI-09/2013. Microchips were cleaned, 
disinfected with ethanol 70% and placed in sterile PBS 
(Gibco). Mice were anesthetized with isoflurane 4%, shaved 
and locally disinfected with Betadine solution; the sterile 
microchips were implanted in the peritoneum and the cavity 
sutured with Vicryl 6.0 (Provet AG). After 30 days, the 
microchips were removed, the peritoneal cavity was rinsed 
with 0.5mL of PBS (Gibco) and the liquid collected and 
centrifuged at 7000rpm for 10’ at 4 °C. As negative control 
peritoneal wash was performed to mice with absence of any 
surgical procedure.  
F. In-vivo biocompatibility tests: assessment of the level of 
inflammation 
The concentration of ATP was determined in the 
supernatant with an ATP determination kit (Invitrogen). For 
polymorphonuclear neutrophils detection, the pellet was re-
suspended in 0.2 mL RPMI 10% Fetal Bovine Serum (Gibco) 
and analyzed at flow cytometer (FACS Canto, Becton 
Dickinson) with antibodies specific for CD11b and Gr1, 
labeled with allophycocyanin (APC) and fluorescein 
isothiocyanate (FITC, BioLegend), respectively. 
III. RESULTS AND DISCUSSION 
The main features of an implantable device that can be 
sources of inflammation are the shape, the materials, and sizes 
of the device [10]. In this paper we compare three different 
packaging realized with different shape, size and with different 
materials. However, they all share some common features: (i) 
MWCNTs were entrapped in a chitosan matrix to prevent the 
potential toxicity due to their nano-particle nature; (ii) to 
prevent the corrosion of electronic components due to the 
contact with biologic fluids, and to prevent the leaking of 
potential hazardous substances, a coating of Parylene C was 
deposited [8, 9]; (iii) a biocompatible packaging was realized, 
as, for an implantable sensor, it is essential for a correct wound 
healing, and for ensuring prolonged sensor functionality. The 
main differences between the three systems are: (i) the shape of 
the device; (ii) the shape of the packaging in silicone; (iii) the 
composition of the membrane that covers the sensors; (iv) the 
composition of the external packaging. All these differences 
are illustrated in Fig. 2.  
To compare the properties of the different designs, the in-
vivo biocompatibility of the implantable devices was 
investigated by subcutaneously implanting the prototypes in 
mice for 30 days. Moreover, in order to test if the position of 
the implant influences the final biocompatibility, the first two 
prototypes were implanted in the back of mice, and the third 
one was implanted in the peritoneum. At the end of the period, 
the implant site was washed with PBS, and levels of ATP and 
neutrophils in the elution liquid were quantified to follow the 
local inflammatory response, as ATP and neutrophils are both 
inflammatory mediators but they give different information.  
Data from ATP and neutrophils for the first prototype, 
depicted in Fig. 3, suggest that after 30 days the host seems to 
accept the insert. Comparison with the commercial chip, level 
of neutrophil, and biocompatibility tests with cell cultures for 
the first version of the packaging have been published in [8]. 
Fig. 4 reports ATP and neutrophil variations in the liquid 
collected from the implant site for the second version of the 
packaging. ATP and neutrophil levels were also evaluated for a 
commercial chip (DATA MARS), for a negative control (mice 
with AP), and in case of artificial inflammation introduced by 
the injection of bacterial lipopolysaccharides (LPS).  
As shown in the last column in Fig. 4, the negative control 
presents a barely detectable concentration of neutrophils, while 
there is still a small amount of extracellular ATP due to 
mechanical stress created during the collection of the fluid. 
Data from both ATP and neutrophil concentration suggest that 




Fig. 3. ATP concentrations (nM) recovered from APs after 30 days from the 
implant of the first version of the implantable device.  
 
Fig. 4. ATP concentrations (nM) and % of neutrophils recovered from APs 
after 30 days from the implant of the second version of the implantable 
device.  
 
Fig. 5. ATP concentrations (nM) and % of neutrophils recovered from APs 
after 30 days from the implant of the third version of the implantable 
device.  
Furthermore, after 30 days, ATP and neutrophil levels are 
comparable with the negative control (AP), as well as for the 
commercial chip, and significantly lower than the positive 
control (LPS), proving that after 30 days the host seems to 
accept the implant.  
We also performed in-vivo biocompatibility tests with the 
third version of the packaging, made by the epoxy enhanced 
polyurethane membrane and a biocompatible silicone, by 
implanting for 30 days four prototypes in the peritoneum of 
mice. The values for ATP and neutrophil concentration are 
reported in Fig. 5. Unfortunately, the level of both ATP and 
neutrophils was still high after 30 days compared to the 
negative control, proving that the host does not tolerate this 
implant, and that the surgery into the peritoneal cavity creates 
extensive cell damages. 
IV. CONCLUSIONS 
From these tests we can conclude that the peritoneum is 
probably not the best place to implant the device, as the mouse 
can easily scratch the suture and increase the level of the 
inflammation. Moreover, data from the tests run with the first 
and second prototypes proved that both the PU-based 
membrane and the packaging made in silicone elastomer 
provide a quite good biocompatible coverage. 
The membrane in polyurethane represents the best solution 
as a membrane for the sensing part, as the deposition technique 
is more reliable and reproducible than the procedure used to fix 
the polycarbonate membrane. 
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